KDM5B and gastric cancer: The capability of compound 27a to stabilize KDM5B in a dose-dependent manner and induce the accumulation of H3K4me2/3 in the gastric cancer cell line MKN45, supports the use of compound 27a as a potent and cellular active KDM5B inhibitor.